Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2015

Pharma News, 2015

Bayer, Regeneron’s Eylea gets additional EU indication
Bayer, Regeneron’s Eylea gets additional EU indication
The European Commission has granted a fifth indication to Bayer and Regeneron’s eye drug Eylea (aflibercept injection), which is now also approved for the treatment of visual impairment due ...
The partnership is to conduct analytical and stability studies of small-molecule new chemical entities
The partnership is to conduct analytical and stability studies of small-molecule new chemical entities
Singapore.
Two-thirds of people under 50 have herpes: WHO
Two-thirds of people under 50 have herpes: WHO
More than 3.
FDA Approves Expanded Use for Melanoma Drug
FDA Approves Expanded Use for Melanoma Drug
THURSDAY, Oct.
Celgene’s VIDAZA® (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
Celgene’s VIDAZA® (Azacitidine for Injection) Approved by the European Commission as New Treatment for Elderly Patients with Acute Myeloid Leukaemia
October 30, 2015 - BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ.
Gilead tees up another hep C combo for FDA review
Gilead tees up another hep C combo for FDA review
Gilead Sciences ($GILD), reaping billions from its duo of approved hepatitis C therapies, is moving toward the market with a third pill that promises to cure a wider range of patients with the...
Novo Nordisk bucks diabetes market pressures with 9% sales growth
Novo Nordisk bucks diabetes market pressures with 9% sales growth
U.
AstraZeneca’s genetic cancer drug Lynparza also works in prostate cancer
AstraZeneca’s genetic cancer drug Lynparza also works in prostate cancer
Anglo-Swedish pharma major AstraZeneca’s (LSE.
Pfizer and Allergan Begin Merger Talks
Pfizer and Allergan Begin Merger Talks
Drug makers Pfizer Inc.
Astellas Inititaties Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia Patients
Astellas Inititaties Phase 3 Registration Trial of gilteritinib (ASP2215) in Relapsed or Refractory Acute Myeloid Leukemia Patients
TOKYO, Japan I October 28, 2015 I Astellas Pharma Inc.
Tel Aviv District Court Rules in Favor of Mylan Listing on Tel Aviv Stock Exchange
Tel Aviv District Court Rules in Favor of Mylan Listing on Tel Aviv Stock Exchange
HERTFORDSHIRE, England and PITTSBURGH, Oct.
Drug-device combination opens potential new path to treat stroke
Drug-device combination opens potential new path to treat stroke
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at ...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand